NASDAQ$SRTA
Strata Critical Medical Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Blade Air Mobility announced Q3 2024 results, marked by revenue growth and strategic advancements.
Blade Air Mobility reported a 4.8% increase in revenue to $74.9 million, driven by growth in the Medical and Short Distance segments. The company achieved positive Passenger Segment Adjusted EBITDA on a trailing twelve-month basis, ahead of schedule. They also announced a strategic alliance with OrganOx to enhance organ transplant logistics.
- Operating Cash Flow increased by $4.3 million to $6.4 million.
- Free Cash Flow, Before Aircraft Acquisitions, increased by $2.4 million to $3.7 million.
- Medical Segment Adjusted EBITDA improved 15.1% compared to the prior year.
- Adjusted EBITDA improved by $3.4 million versus the prior year to $4.2 million.
Headline financials
Revenue & EPS history
Strata Critical Medical · Revenue · Quarterly
$74.9M
Forward guidance
For the full year 2024, Blade expects revenue of $240 million to $250 million and positive Adjusted EBITDA. For the full year 2025, the company anticipates double-digit Medical revenue growth, Passenger revenue of $85 million to $95 million, and double-digit millions of Adjusted EBITDA.
Tailwinds
- Revenue of $240 million to $250 million is expected for 2024.
- Positive Adjusted EBITDA is expected for 2024.
- Double-digit Medical revenue growth is expected for 2025.
- Passenger revenue of $85 million to $95 million is expected for 2025.
- Double-digit millions of Adjusted EBITDA is expected for 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+3.4%
Avg return
Earnings day
+2.8%
Avg return
5 days after
+5.7%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+38.8%
Q3 2023
Best reaction
-32.1%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.6% | +17.2% | +19.7% | |
| Q4 2025 | +6.9% | +1.1% | -7.6% | |
| Q3 2025 | +9.5% | +8.1% | +4.3% | |
| Q1 2025 | +18.7% | +20.5% | +41.4% | |
| Q4 2024 | +7.1% | +8.1% | -4.9% | |
| Q3 2024 | -4.4% | -17.5% | +8.9% | |
| Q2 2024 | +17.3% | +3.6% | +2.9% | |
| Q1 2024 | -3.3% | -3.3% | -16.0% | |
| Q4 2023 | -32.1% | -32.3% | -3.5% | |
| Q3 2023 | +38.8% | +44.5% | +44.5% | |
| Q2 2023 | -7.9% | -6.7% | -24.3% | |
| Q1 2023 | +9.4% | +2.8% | +28.1% | |
| Q4 2022 | -9.7% | -22.3% | -32.0% | |
| Q3 2022 | -2.3% | -0.2% | +3.4% | |
| Q2 2022 | +8.0% | +6.9% | -17.5% | |
| Q1 2022 | -15.0% | +0.9% | -2.3% | |
| Q4 2021 | -3.2% | +5.2% | -2.0% | |
| Q3 2021 | +0.3% | +2.1% | +41.4% | |
| Q2 2021 | +18.0% | +16.4% | +58.7% | |
| Q1 2021 | +13.7% | +11.8% | -11.8% | |
| Q4 2020 | -0.1% | -0.1% | +3.1% | |
| Q2 2020 | +0.0% | -0.2% | -0.1% | |
| Q1 2020 | +1.0% | +1.0% | +1.3% | |
| Q4 2019 | -0.2% | -0.3% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro